Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Gusstoon Apr 17, 2018 9:37am

119 Views

Post# 27896403

level 2

Level ll Quote
Bid			Ask
Price	Total Size	# of Orders	Price	Total Size	# of Orders

$0.165	117000	5	$0.17	36500	1
$0.16	624000	24	$0.175	73000	6
$0.155	220000	12	$0.18	66000	8
$0.15	371500	27	$0.185	82500	3
$0.145	126000	10	$0.19	82000	7
$0.14	168000	12	$0.195	81000	5
$0.135	72500	7	$0.20	66500	9
$0.13	273000	12	$0.205	37000	3
$0.125	12500	3	$0.21	110500	6
$0.12	69000	6	$0.215	88500	4